Human and nonclinical disposition of [14C]bictegravir, a potent integrase strand-transfer inhibitor for the treatment of HIV-1 infection
Bictegravir (BIC) is a potent small-molecule integrase strand-transfer inhibitor (INSTI) and a component of Biktarvy®, a single-tablet combination regimen that is currently approved for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. The absorption, metabolism, distribution, and elimination (ADME) characteristics of BIC were determined through in vivo nonclinical and clinical studies (IND 121318).[14C]BIC was rapidly absorbed orally in mice, rats, monkeys and human. The cumulative dose recovery was high in nonclinical species (>80%) and humans (95.3%), with most of the excreted dose recovered in faeces. Quantifiable radioactivity with declining concentration was observed in rat tissues suggesting reversible binding. Unchanged BIC was the most abundant circulating component in all species along with two notable metabolites M20 (a sulphate conjugate of hydroxylated BIC) and M15 (a glucuronide conjugate of BIC). BIC was primarily eliminated by hepatic metabolism followed by excretion of the biotransformed products into faeces. In vitro drug-drug interaction (DDI) studies with M15 and M20 demonstrated that no clinically relevant interactions were expected.Overall, BIC is a novel and potent INSTI with a favourable resistance, PK, and ADME profile that provides important improvements over other currently available INSTIs for the treatment of HIV-1.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:52 |
|---|---|
| Enthalten in: |
Xenobiotica; the fate of foreign compounds in biological systems - 52(2022), 9-11 vom: 21. Sept., Seite 973-985 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Subramanian, Raju [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 25.01.2023 Date Revised 01.02.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/00498254.2022.2159569 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM350579962 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM350579962 | ||
| 003 | DE-627 | ||
| 005 | 20231226045320.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/00498254.2022.2159569 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1168.xml |
| 035 | |a (DE-627)NLM350579962 | ||
| 035 | |a (NLM)36546430 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Subramanian, Raju |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Human and nonclinical disposition of [14C]bictegravir, a potent integrase strand-transfer inhibitor for the treatment of HIV-1 infection |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.01.2023 | ||
| 500 | |a Date Revised 01.02.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Bictegravir (BIC) is a potent small-molecule integrase strand-transfer inhibitor (INSTI) and a component of Biktarvy®, a single-tablet combination regimen that is currently approved for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. The absorption, metabolism, distribution, and elimination (ADME) characteristics of BIC were determined through in vivo nonclinical and clinical studies (IND 121318).[14C]BIC was rapidly absorbed orally in mice, rats, monkeys and human. The cumulative dose recovery was high in nonclinical species (>80%) and humans (95.3%), with most of the excreted dose recovered in faeces. Quantifiable radioactivity with declining concentration was observed in rat tissues suggesting reversible binding. Unchanged BIC was the most abundant circulating component in all species along with two notable metabolites M20 (a sulphate conjugate of hydroxylated BIC) and M15 (a glucuronide conjugate of BIC). BIC was primarily eliminated by hepatic metabolism followed by excretion of the biotransformed products into faeces. In vitro drug-drug interaction (DDI) studies with M15 and M20 demonstrated that no clinically relevant interactions were expected.Overall, BIC is a novel and potent INSTI with a favourable resistance, PK, and ADME profile that provides important improvements over other currently available INSTIs for the treatment of HIV-1 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Bictegravir | |
| 650 | 4 | |a HIV-1 | |
| 650 | 4 | |a human disposition | |
| 650 | 4 | |a nonclinical disposition | |
| 650 | 4 | |a radioactivity | |
| 650 | 4 | |a single-tablet combination regimen | |
| 650 | 7 | |a bictegravir |2 NLM | |
| 650 | 7 | |a 8GB79LOJ07 |2 NLM | |
| 650 | 7 | |a HIV Integrase Inhibitors |2 NLM | |
| 650 | 7 | |a Pyridones |2 NLM | |
| 650 | 7 | |a Amides |2 NLM | |
| 650 | 7 | |a Heterocyclic Compounds, 3-Ring |2 NLM | |
| 650 | 7 | |a Heterocyclic Compounds, 4 or More Rings |2 NLM | |
| 650 | 7 | |a Integrases |2 NLM | |
| 650 | 7 | |a EC 2.7.7.- |2 NLM | |
| 700 | 1 | |a Ling, John |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Jianhong |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Kelly |e verfasserin |4 aut | |
| 700 | 1 | |a Hao, Jia |e verfasserin |4 aut | |
| 700 | 1 | |a Jin, Haolun |e verfasserin |4 aut | |
| 700 | 1 | |a Lai, Yurong |e verfasserin |4 aut | |
| 700 | 1 | |a Murray, Bernard |e verfasserin |4 aut | |
| 700 | 1 | |a Wijaya, Samantha |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Heather |e verfasserin |4 aut | |
| 700 | 1 | |a Smith, Bill J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Xenobiotica; the fate of foreign compounds in biological systems |d 1971 |g 52(2022), 9-11 vom: 21. Sept., Seite 973-985 |w (DE-627)NLM000064742 |x 1366-5928 |7 nnns |
| 773 | 1 | 8 | |g volume:52 |g year:2022 |g number:9-11 |g day:21 |g month:09 |g pages:973-985 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/00498254.2022.2159569 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 52 |j 2022 |e 9-11 |b 21 |c 09 |h 973-985 | ||